New injection shows promise for shedding pounds in early trial

NCT ID NCT07114419

Recruiting now Disease control Sponsor: Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called efsubaglutide alfa for weight loss in 200 adults who are overweight or obese. Participants receive weekly or biweekly injections for 22 weeks, and researchers measure how much weight they lose. The goal is to see if the drug is safe and effective compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efsubaglutide alfa (a drug injection for weight loss)
What this could lead to: If successful, this could lead to a new treatment option for weight loss in people with overweight or obesity.
What could go wrong: This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND OVERWEIGHT

Contacts and locations

Locations

Canopy Clinical Altona North
RECRUITING

North Altona, Australia
Canopy Clinical Northern Beaches
RECRUITING

Brookvale, Australia
Canopy Clinical Sutherland Shire
RECRUITING

Miranda, Australia
Canopy Clinical Wollongong
RECRUITING

Wollongong, Australia
Fusion Clinical Research
RECRUITING

Norwood, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.